Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.
Office of Clinical Pharmacology, Office of Translational Sciences, Centre for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
CPT Pharmacometrics Syst Pharmacol. 2020 Jun;9(6):310-321. doi: 10.1002/psp4.12509. Epub 2020 May 22.
Creatinine is the most common clinical biomarker of renal function. As a substrate for renal transporters, its secretion is susceptible to inhibition by drugs, resulting in transient increase in serum creatinine and false impression of damage to kidney. Novel physiologically based models for creatinine were developed here and (dis)qualified in a stepwise manner until consistency with clinical data. Data from a matrix of studies were integrated, including systems data (common to all models), proteomics-informed in vitro-in vivo extrapolation of all relevant transporter clearances, exogenous administration of creatinine (to estimate endogenous synthesis rate), and inhibition of different renal transporters (11 perpetrator drugs considered for qualification during creatinine model development and verification on independent data sets). The proteomics-informed bottom-up approach resulted in the underprediction of creatinine renal secretion. Subsequently, creatinine-trimethoprim clinical data were used to inform key model parameters in a reverse translation manner, highlighting best practices and challenges for middle-out optimization of mechanistic models.
肌酸酐是肾功能最常用的临床生物标志物。作为肾转运体的底物,其分泌易受药物抑制,导致血清肌酸酐短暂升高,给人造成肾脏损伤的假象。本文采用逐步淘汰的方法,开发了新型基于生理学的肌酸酐模型,并对其进行了合格性评估,直至与临床数据相一致。整合了一系列研究的数据,包括所有模型共有的系统数据、基于蛋白质组学的体外-体内外推所有相关转运体清除率、外源性给予肌酸酐(估计内源性合成率)以及抑制不同的肾转运体(在肌酸酐模型开发过程中,考虑了 11 种有资格的促效剂药物,并在独立数据集上进行了验证)。基于蛋白质组学的自下而上方法导致对肌酸酐肾分泌的预测不足。随后,使用肌酸酐-甲氧苄啶的临床数据以逆向翻译的方式为关键模型参数提供信息,突出了机械模型的中间优化的最佳实践和挑战。